title: TKIs may be option for Ph-like ALL.
abstract: A recently identified subtype of acute lymphoblastic leukemia called Ph-like ALL is driven by an assortment of genetic changes that activate kinase signaling--alterations that may be vulnerable to FDA-approved tyrosine kinase inhibitors.
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors